KorinMi raises US$1.36M from Lotus Herbals to bring K-beauty clinics across India
What's the deal? Gurugram-based Korean beauty clinic KorinMiDealroom has a profile for this one. Try Dealroom → has raised US$1.36M from Lotus HerbalsDealroom has a profile for this one. Try Dealroom →' innovation fund, which has US$32.4M corpus dedicated to early-stage beauty and wellness startups in India.
Founded in 2024, KorinMi operates three clinics in Gurugram offering Korean-style skin and hair treatments, and has expanded into direct-to-consumer (D2C) products made in South Korea. The startup says it has served over 3,000 clients since launching its first clinic in October 2024.
Co-founded by CEO Reshbha Munjal and COO Jenovia Daun Jung — a South Korean national with experience in the K-beauty industry — the company plans to use the funds to open clinics in Mumbai, Bengaluru, and Hyderabad.
Why now? K-beauty — an umbrella term for skincare, makeup, and treatments originating in South Korea — has gained global traction for its focus on long-term skin health over quick fixes. India's beauty and wellness market is growing fast, and established players are racing to back emerging segments.
This is the third investment from the Lotus Innovation Fund, launched in June 2024. Nitin Passi, managing director of Lotus Herbals, said the investment was about diversifying into beauty and skincare segments where it doesn't currently operate. In May 2025, KorinMi had raised US$407.4K from former Kaya Skin ClinicDealroom has a profile for this one. Try Dealroom → (UAE) chief executive officer Vikas AgarwalDealroom has a profile for this one. Try Dealroom → and other angel investors.
What could go wrong? Scaling a clinic-based model across Indian cities is operationally complex. Each KorinMi location requires at least two doctors, a network of dermatologists, and six to seven therapists — plus specialised equipment and products imported from South Korea.
The company's D2C products, made in Korea but tailored for Indian skin types and weather, add another layer of supply chain risk. Convincing price-sensitive Indian consumers to pay a premium for Korean treatments in a market crowded with domestic alternatives won't be easy either.
The signal: This is only the third bet from the Lotus Innovation Fund since its June 2024 launch, suggesting the corporate investor is being highly selective about where it deploys its $50 million corpus. The choice of a clinic-based model — rather than yet another D2C brand — hints that legacy beauty corporates see services, not just products, as the next growth frontier in India's beauty economy.
Read more: economictimes.indiatimes.com
